Jump to Main Content

About ASH

Scientific Committee on Hematopoiesis

Committee Roster

Keisuke Ito, MD, PhD  ('24)

Vice Chair
Claudia Waskow, PhD  ('24)

Appointed Members
Iannis Aifantis, PhD  ('24)
Stephanie Halene, MD  ('26)
Dirk Loeffler, PhD  ('25)
Christopher  Y. Park, MD, PhD  ('25)
Ingo Ringshausen, MD  ('24)
Caner Saygin, MD  ('27)
Dhvanit  I Shah, PhD, PharmD  ('24)
Momoko Yoshimoto, MD, PhD  ('26)

Staff Liaison
Alice Kuaban, MS

Committee Mandate

The Scientific Committee on Hematopoiesis focuses on the areas related to hematopoietic stem/progenitor intrinsic as well as microenvironment (non cell-autonomous) related cellular and molecular mechanisms in the context of normal and pathological processes in adult and developmental hematopoiesis. Although there may be significant overlap with other scientific committees, our charge will primarily be to focus on the fundamental biology and molecular actions during normal and dysregulated blood cell production and to highlight specific genes, proteins or regulatory networks that contribute to normal hematopoiesis but are altered in inherited or acquired bone marrow failure syndromes or stem/progenitor cell transformation.

The areas of focus by the Scientific Committee on Hematopoiesis include but are not limited to: preclinical aspects and their clinical implications (diagnosis and treatment) of lymphopoiesis, myelopoiesis, erythropoiesis and megakaryocytic/platelet disorders. In particular, this committee will emphasize the molecular and cellular mechanisms related to hematopoietic stem cell maintenance and cell fate decision, stem cell survival and metabolism, multipotent and lineage-specific progenitor development, clonal evolution, and differentiation. These mechanisms include those involved in stress response, tumor/leukemia initiation and progression, and blood cell-microenvironment interaction critical for both normal and malignant hematopoiesis.

Finally the committee will promote innovative approaches of genetic, epigenetic, and whole genome analyses of normal stem cell and linage-specific stem/progenitor cell development, and the association with pre-malignant and malignant hematologic diseases and inherited normal variants that may contribute to the development of disorders of hematopoiesis.

There is potential overlap with:

  1. Myeloid Biology – mechanisms of myelopoiesis and evolution of myeloid progenitors and diseases including myeloid leukemia
  2. Myeloid Neoplasia – myeloid leukemia, myeloproliferative disorders, myelodysplastic syndrome, transformation in myeloid progenitors
  3. Stem Cells and Regenerative Medicine – hematopoietic stem cell and multipotent progenitor cell regulations, stem cell self-renewal and maintenance, stem cell regeneration and reprogramming

Appropriate sessions at the annual meeting may include:

  • Multipotential and lineage-committed hematopoietic progenitor and stem cells – development, evolution, lineage determination, regulatory mechanisms, translational potential, and clinical therapies
  • Stem/progenitor cell regulation by soluble factors and via interaction with microenvironment – novel cellular and molecular insights
  • Molecular networks and pathways that govern hematopoietic stem/progenitor self-renewal, survival, differentiation, transformation and potential clinical applications
  • Joint sessions with the Scientific Committee on Stem Cells and Regenerative Medicine or Scientific Committee on Myeloid Biology may be considered periodically